Background:

AARS(alanyl-tRNA synthetase) is also named as AlaRS(alanine tRNA ligase 1, cytoplasmic), renal carcinoma antigen NY-REN-42 and belongs to the class-II aminoacyl-tRNA synthetase family. It can interpret the RNA code and attach specific aminoacids to the tRNAs that contain the cognate trinucleotide anticodons. AARS consists of three domains: the N-terminal catalytic domain, the editing domain and the C-terminal C-Ala domain. The editing domain removes incorrectly charged amino acids, while the C-Ala domain, along with tRNA(Ala), serves as a bridge to cooperatively bring together the editing and aminoacylation centers thus stimulating deacylation of misacylated tRNAs(PMID:19661429).

Clonality:

polyclonal

Classification:

Primary antibody

Alternative names:

AARS, Alanine tRNA ligase, alanyl tRNA synthetase, AlaRS

Specificity:

Human, Mouse, Rat

Host:

Rabbit

Isotype:

IgG

Immunogen:

alanyl-tRNA synthetase

Purification:

Immunogen affinity purified

Purity:

≥95% as determined by SDS-PAGE

Calculated molecular weight:

107 kDa

Form:

liquid

Applications:

ELISA, WB, IHC, IF, IP

Recommended dilution:

WB: 1:200-1:1000; IHC: 1:20-1:200; IF: 1:20-1:200; IP: 1:200-1:2000

Storage:

PBS with 0.02% sodium azide and 50% glycerol pH 7.3,-20℃ for 12 months(Avoid repeated freeze / thaw cycles.)

More info:

Email: info@sobekbio.com

Orders:

Email: orders@sobekbio.com